The current financial score of Editas Medicine Inc is 9.04. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 11.89M, representing a year-over-year increase of 232.31%, while its net profit experienced a year-over-year increase of 65.76%.
The current valuation score of Editas Medicine Inc is 6.50. Its current P/E ratio is -2.36, which is -86.36% below the recent high of -0.32 and -132.29% above the recent low of -5.49.
The current earnings forecast score of Editas Medicine Inc is 7.23. The average price target is 6.14, with a high of 15.00 and a low of 1.00.
The current price momentum score of Editas Medicine Inc is 5.65. Currently, the stock price is trading between the resistance level at 3.28 and the support level at 2.35, making it suitable for range-bound swing trading.
The current institutional shareholding score of Editas Medicine Inc is 5.00. The latest institutional shareholding proportion is 52.11%, representing a quarter-over-quarter decrease of 22.13%. The largest institutional shareholder is James Simons, holding a total of 2.47M shares, representing 0.01% of shares outstanding, with 507.28% increase in holdings.
The current risk assessment score of Editas Medicine Inc is 4.17. The company's beta value is 2.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.